Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
April 25, 2024 06:00 ET
|
Coave Therapeutics
Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2024 Annual Meeting
April 24, 2024 09:00 ET
|
Doheny Eye Institute
PASADENA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and...
Verana Health Announces Launch of Qdata® Thyroid Eye Disease
April 24, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today...
Glaucoma Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Points Status
April 24, 2024 08:38 ET
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Glaucoma - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report,...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024 07:13 ET
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
April 16, 2024 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and...
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
April 16, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
April 16, 2024 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...